The data also showed that LOR-253 has significant anticancer activity against non-small-cell lung cancer, particularly in tumors with low expression levels of the tumor suppressor Krüppel-like factor 4

Proceeds will be used to initiate the pivotal Phase III of HA-Irinotecan, a topoisomerase I inhibitor targeting small-cell lung cancer...Aslan will fund and conduct development of the molecule under a pre-agreed development program that will initially target gastric cancer and lung cancer

Aslan will fund and conduct development of the molecule under a pre-agreed development program that will initially target gastric cancer and lung cancer

OncoGenex Pharmaceuticals Inc., of Bothell, Wash., reported that preclinical data evaluating its investigational compound, OGX-427, in pancreatic cancer are consistent with previously published studies in bladder, prostate and lung cancers, where expression of Hsp27 was correlated with the promotion of tumor cell growth and treatment resistance

The drug is already approved by the FDA for non-small-cell lung cancer and esophageal cancer

Agennix AG, of Planegg, Germany, said data from a Phase II study of oral immunotherapy talactoferrin in patients with previously treated non-small-cell lung cancer showed it achieved its primary endpoint of improvement in overall survival

Stimuvax is in Phase III testing in non-small-cell lung cancer

Stimuvax is in Phase III testing in non-small-cell lung cancer

Interim results from a Phase II trial in non-small-cell lung cancer showed evidence of improved disease control and greater progression-free survival compared to chemotherapy alone...Other Phase II results in ovarian and small-cell lung cancer showed long-term clinical benefit, and Phase I results established safety of a high dose level with two-hour infusion

Adventrx Pharmaceuticals Inc., of San Diego, said the FDA determined in a meeting to discuss the complete response letter for lung cancer drug Exelbine (vinorelbine injectable emulsion) that while no clinical deficiencies were noted, the agency could not accept alternate methods of verifying the authenticity of the study drug, and the bioequivalence study would have to be repeated

Eli Lilly and Co., of Indianapolis, received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the use of Alimta (pemetrexed for injection) as continuation maintenance therapy in patients with advanced nonsquamous non-small-cell lung cancer

Alchemia Ltd., of Brisbane, Australia, began recruitment for a Phase II trial of its cancer candidate HA-Irinotecan for small-cell lung cancer

Arch Biopartners Inc., of Toronto, said it identified a lead compound, named GH501a, for further development as a potential treatment for non-small-cell lung cancer and pancreatic cancer

Helsinn Group, of Lugano, Switzerland, initiated a pivotal program for anamorelin in anorexia/cachexia associated with advanced non-small-cell lung cancer

The FDA approved Xalkori (crizotinib) by Pfizer Inc., of New York, for non-small-cell lung cancer (NSCLC

Qiagen NV, of Venlo, the Netherlands, and Pfizer Inc., of New York, inked a partnership to develop a molecular diagnostic test for use with Pfizer's investigational compound, dacomitinib (PF-00299804), an oral inhibitor of HER-1 (EGFR) and other tyrosine kinases that is in clinical development for the treatment of non-small-cell lung cancer

Qiagen NV, of Venlo, the Netherlands, and Pfizer Inc., of New York, inked a partnership to develop a molecular diagnostic test for use with Pfizer's investigational compound, dacomitinib (PF-00299804), an oral inhibitor of HER-1 (EGFR) and other tyrosine kinases that is in clinical development for the treatment of non-small-cell lung cancer

The data also showed CPI-613 inhibited tumor growth in a non-small-cell human lung cancer and a human pancreatic cancer in a mouse tumor model

Sapacitabine, a cell cycle modulating nucleoside analogue, is in Phase III testing in acute myeloid leukemia in elderly patients and in Phase II trials for myelodysplastic syndromes and lung cancer